SHILPAMEDNSEShilpa Medicare Limited· PharmaceuticalsLowNeutral
Announced Tue, 26 Aug · 15:53 IST

Shilpa Medicare Limited has informed the Exchange regarding Pursuant to regulation 34(2) (f) of Securities and Exchange Board of India (Listing Obligations and DisclosureRequirements) Regulations, 2015, please find enclosed copy of Business Responsibility and Sustainability Report (BRSR) for the FY 2024-25 which forms an integral part of the Annual report for FY 2024-25''.

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Shilpa Medicare Limited has filed its Business Responsibility and Sustainability Report (BRSR) for FY 2024-25, which forms part of its Annual Report. The company is a pharmaceutical formulations maker, with 99% of turnover from formulations and a strong export focus of 91.58%, serving 74 countries. Key financials reported include turnover of ₹477.34 crore and net worth of ₹2,637.15 crore. The company employs 898 permanent employees and 100 permanent workers, and highlights commitments to reach 95% renewable energy by 2030 and net-zero carbon by 2050. Certifications held include ISO 14001, ISO 45001, ISO 50001, and SA 8000, with 100% of employees and workers trained on health and safety. No external assurance was obtained for the BRSR, no work-related fatalities or injuries were reported, and gender diversity remains low with only 5.23% of permanent employees being women and 16.67% of board seats held by women. High employee turnover of 54.25% was noted, and 50% of inputs were reported as sustainably sourced.

Likely market impact

This is a routine regulatory compliance filing and is unlikely to move the stock on its own. However, the disclosure highlights rising employee turnover, low gender diversity, and 95.48% related-party purchases, which ESG-focused investors may flag as areas of concern.